Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Recursion Pharmaceuticals Inc RXRX

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative... see more

NDAQ:RXRX - Post Discussion

Recursion Pharmaceuticals Inc > RXRX is up 14% after hrs with good vol, i cant find any news
View:
Post by Humanist on Feb 14, 2024 6:32pm

RXRX is up 14% after hrs with good vol, i cant find any news

anyone have any idea?
Comment by jacobite on Feb 26, 2024 12:35pm
I have to think it's riding the NVDA tailwind after their buy in last summer
Comment by 5oceans on Nov 27, 2024 3:55pm
Yah ... well, that kind of activity IMO, is big money doing its thing.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities